The Use of GLP1R Agonists for the Treatment of Type 2 Diabetes in Kidney Transplant Recipients.
Journal
Transplantation direct
ISSN: 2373-8731
Titre abrégé: Transplant Direct
Pays: United States
ID NLM: 101651609
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
04
11
2019
accepted:
25
11
2019
entrez:
26
2
2020
pubmed:
26
2
2020
medline:
26
2
2020
Statut:
epublish
Résumé
Glucagon-like peptide-1 receptor agonists (GLP1RA) have been shown to improve glucose control and diabetes-related comorbidities in patients without solid organ transplants. The effectiveness, safety, and tolerability of GLP1RA after kidney transplantation have not been adequately studied. We retrospectively reviewed data on kidney transplant recipients performed in our institution, who were initiated on GLP1RA either for the treatment of type 2 diabetes diagnosed before transplantation or posttransplant diabetes. We analyzed efficacy, safety, and the effect on kidney allograft function. Seventeen kidney transplant recipients were initiated on GLP1RA therapy, 14 of which remained on the medication for at least 12 months. The use of GLP1RA had no significant impact on weight loss, but was associated with a significant reduction in the total daily insulin dose, from the median of 63 [interquartile range 43-113] IU to 44 [interquartile range 25-88] and reduction in the risk of hypoglycemia in patients who were on therapy for at least approximately 12 months. Kidney function remained stable and none of the recipients experienced acute rejection. Tacrolimus dose was not significantly changed. Five patients (29%) discontinued GLP1RA therapy-4 due to side effects and 1 due to uncontrolled hyperglycemia. GLP1RA may be a relatively safe and effective treatment for kidney transplant recipients with type 2 diabetes that allows for a reduction in insulin requirements. More studies are needed to determine whether the use of these agents will translate into an improvement in allograft and patient survival.
Identifiants
pubmed: 32095510
doi: 10.1097/TXD.0000000000000971
pmc: PMC7004635
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e524Subventions
Organisme : NIDDK NIH HHS
ID : K23 DK123313
Pays : United States
Informations de copyright
Copyright © 2020 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors declare no funding or conflicts of interest.
Références
Transplant Proc. 2014 Dec;46(10):3383-9
pubmed: 25498056
Obesity (Silver Spring). 2019 Feb;27(2):309-314
pubmed: 30677260
Lancet. 1998 Sep 12;352(9131):854-65
pubmed: 9742977
N Engl J Med. 2017 Aug 31;377(9):839-848
pubmed: 28854085
Diabetes Care. 2013 Oct;36(10):e171-2
pubmed: 24065848
Am J Transplant. 2019 Feb;19 Suppl 2:19-123
pubmed: 30811893
Diabetes Technol Ther. 2015 Jan;17(1):35-42
pubmed: 25375397
Diabetes Care. 2019 Jan;42(Suppl 1):S90-S102
pubmed: 30559235
Nat Rev Endocrinol. 2019 Mar;15(3):172-188
pubmed: 30622369
Circulation. 2019 Apr 23;139(17):2022-2031
pubmed: 30786725
BMJ. 2012 Apr 19;344:e1771
pubmed: 22517929
Diabetes Care. 2019 Apr;42(4):625-634
pubmed: 30765434
N Engl J Med. 2016 Nov 10;375(19):1834-1844
pubmed: 27633186
Am J Transplant. 2018 Jan;18(1):180-188
pubmed: 28710896
Ann Intern Med. 1999 Mar 16;130(6):461-70
pubmed: 10075613
Kidney Int. 2014 Mar;85(3):579-89
pubmed: 24152968
BMJ. 2018 Oct 12;363:k4065
pubmed: 30314981
Transplantation. 2002 Sep 15;74(5):675-81
pubmed: 12352885
Diabetes Obes Metab. 2017 Sep;19(9):1233-1241
pubmed: 28244632
Diabetes Res Clin Pract. 2019 Sep;155:107785
pubmed: 31326453
Semin Dial. 2014 Mar;27(2):135-45
pubmed: 24588802
Diabetes Obes Metab. 2018 Dec 18;:
pubmed: 30565376
Transplant Rev (Orlando). 2015 Jul;29(3):145-53
pubmed: 25641399
Postgrad Med. 2018 May;130(4):381-393
pubmed: 29667921
Am J Transplant. 2005 Dec;5(12):2922-8
pubmed: 16303006
Nephrol Dial Transplant. 2003 May;18 Suppl 1:i12-5
pubmed: 12738758
Nat Rev Endocrinol. 2018 Jul;14(7):390-403
pubmed: 29728598
Am J Transplant. 2014 Sep;14(9):1992-2000
pubmed: 25307034
Lancet Diabetes Endocrinol. 2018 Aug;6(8):605-617
pubmed: 29910024
Diabetes Care. 2018 Feb;41(2):267-276
pubmed: 29183910
J Am Soc Nephrol. 2015 Jan;26(1):20-9
pubmed: 25097209
Endocr Rev. 2016 Feb;37(1):37-61
pubmed: 26650437
Semin Dial. 2010 Mar-Apr;23(2):163-8
pubmed: 20210915
J Am Soc Nephrol. 2013 Nov;24(11):1727-36
pubmed: 24115475
Diabetes Care. 2018 Jan;41(Suppl 1):S13-S27
pubmed: 29222373
Am J Nephrol. 2017 Dec 13;46(6):462-472
pubmed: 29253846
Diabetes Ther. 2015 Sep;6(3):239-56
pubmed: 26271795
Am Heart J. 2013 Nov;166(5):823-30.e5
pubmed: 24176437
Diabetes Obes Metab. 2017 Apr;19(4):473-481
pubmed: 27987248
Transplant Proc. 2018 Oct;50(8):2502-2505
pubmed: 30316386
Lancet Diabetes Endocrinol. 2016 Apr;4(4):337-49
pubmed: 26632096
Diabetes Care. 2011 Oct;34(10):2141-5
pubmed: 21949218